Xu Haili, Radabaugh Timothy, Lu Zhenqiang, Galligan Michael, Billheimer Dean, Vercelli Donata, Wright Anne L, Monks Terrence J, Halonen Marilyn, Lau Serrine S
Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, AZ, USA.
Department of Pharmacology, The University of Arizona, Tucson, AZ, USA.
Pediatr Allergy Immunol. 2016 Nov;27(7):696-701. doi: 10.1111/pai.12613. Epub 2016 Sep 12.
Proteomic approaches identifying biomarkers have been applied to asthma to only a very limited extent.
With an antibody array (RayBiotech, Norcross, GA, USA), the relative intensity and rank differences of 444 proteins were compared in 24 plasma samples obtained at age 3, 11 from children with and 12 without asthma diagnoses at ages 5 and 9. Protein candidates identified by antibody array were quantitated by ELISA in an enlarged sample. Proteins found to differentiate children with and without asthma were also examined for association with known Year 1 asthma risk factors, eczema, and wheeze.
In the antibody array, four proteins had rank differences between asthma and non-asthma groups (FDR <0.1). By ELISA, mean log (±s.e.m.) erythropoietin (EPO) level (IU/l) was lower (0.750 ± 0.048 vs. 0.898 ± 0.035; p = 0.006) and mean (±s.e.m.) soluble GP130 (sGP130) level (ng/ml) was higher in the asthma vs. the non-asthma group (302 ± 13 vs. 270 ± 8; p = 0.041). The other 2 array proteins (galactin-3 and eotaxin-3) did not differ by ELISA by asthma. EPO related to the asthma risk factor, first year eczema, whereas sGP130 related to first year wheeze.
Through two independent assessments, age 3 plasma levels of EPO and sGP130 were found related to childhood asthma.
蛋白质组学方法在识别生物标志物方面应用于哮喘的程度非常有限。
使用抗体芯片（美国佐治亚州诺克罗斯的RayBiotech公司），比较了24份血浆样本中444种蛋白质的相对强度和排名差异，这些样本来自5岁和9岁时被诊断为哮喘的儿童以及未患哮喘的儿童在3岁和11岁时采集的样本。通过酶联免疫吸附测定（ELISA）对抗体芯片鉴定出的蛋白质候选物在扩大样本中进行定量分析。还研究了那些被发现能区分患哮喘和未患哮喘儿童的蛋白质与已知的1岁时哮喘风险因素、湿疹和喘息之间的关联。
在抗体芯片检测中，有四种蛋白质在哮喘组和非哮喘组之间存在排名差异（错误发现率<0.1）。通过ELISA检测，哮喘组促红细胞生成素（EPO）的平均对数（±标准误）水平（IU/l）较低（0.750±0.048 vs. 0.898±0.035；p = 0.006），而可溶性糖蛋白130（sGP130）的平均（±标准误）水平（ng/ml）在哮喘组高于非哮喘组（302±13 vs. 270±8；p = 0.041）。另外两种芯片检测出的蛋白质（半乳糖凝集素-3和嗜酸性粒细胞趋化因子-3）通过ELISA检测在哮喘组之间无差异。EPO与哮喘风险因素1岁时的湿疹相关联，而sGP130与1岁时的喘息相关联。
通过两项独立评估，发现3岁时血浆中EPO和sGP130水平与儿童哮喘有关。
